Dr. Patibandla presented a consecutive series of 51 parafascicular intraventricular tumor resections, representing the first documented Indian adoption and the largest reported series to date using ...

Limited announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants ...

A recently hosted research day, through departmental collaboration within the Faculty of Health Sciences, brought together ...

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement ...